drugset / Trial / NCT04349241
Efficacy and Safety of Favipiravir in Management of COVID-19
RandomizedParallel-groupOpen-labelTreatment
Summary
Randomized controlled interventional trial (Clinical Trial) phase 3 to assess the safety and efficacy of favipiravir versus the standard care therapy in the treatment of patients with COVID-19.
Timeline
- Start
- 2020-04-18
- Primary completion
- 2020-06-01
- Completion
- 2020-06-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Favipiravir | Small molecule | 1200 mg | — |
| Comparator | Hydroxychloroquine | Small molecule | 200 mg | — |
| Comparator | Oseltamivir | Small molecule | 75 mg | — |